By Srdan Verstovsek, MD, PhD The VERIFY trial polycythemia vera study examines Rusfertide (PTG-300), a hepcidin mimetic, for patients with polycythemia vera (PV). Presented at ASH 2022 (Poster #1709), this Phase 3 study builds on Phase 2 results. Specifically, it assesses Rusfertide’s ability to reduce phlebotomy needs. So, how does it function, and what could … Continue reading VERIFY Trial: Rusfertide for Polycythemia Vera Patients